8-K/A: Ligand Pharmaceuticals Completes XOMA Royalty Merger

Ligand Pharmaceuticals Incorporated has filed an amendment to its Current Report on Form 8-K to include the financial statements of XOMA Royalty Corporation and pro forma combined financial information following their previously announced merger.

Summary

• Ligand Pharmaceuticals Incorporated (Ligand) has filed an amendment (Form 8-K/A) to its initial Current Report on Form 8-K dated July 14, 2026.
• This amendment serves to include the audited financial statements of XOMA Royalty Corporation for the fiscal year ended December 31, 2025, and its unaudited condensed consolidated financial statements for the six months ended June 30, 2026.
• Additionally, the filing provides unaudited pro forma combined consolidated financial information for Ligand and XOMA Royalty, reflecting the merger as if it had occurred on June 30, 2026, for the balance sheet, and January 1, 2025, for the statements of operations.
• The merger was completed on July 14, 2026, pursuant to an Agreement and Plan of Merger dated April 27, 2026, as amended.
• The pro forma financial information is presented for informational purposes and does not represent the actual results of the combined company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the completion of the merger and the inclusion of detailed financial statements for the acquired entity, which provides greater transparency. However, the pro forma nature of the combined financials and the ongoing integration process introduce some uncertainty.

Positives

• Completion of the merger between Ligand Pharmaceuticals and XOMA Royalty Corporation, as announced on July 14, 2026.
• Inclusion of audited financial statements for XOMA Royalty for the fiscal year ended December 31, 2025.
• Inclusion of unaudited condensed consolidated financial statements for XOMA Royalty for the six months ended June 30, 2026.
• Provision of unaudited pro forma combined consolidated financial information, offering insight into the potential combined entity's financial position and performance.
• The filing provides necessary financial disclosures to comply with SEC requirements following the merger.

Negatives

• The pro forma financial information is presented for informational purposes only and does not represent actual results, meaning the combined company's future performance may differ.
• The pro forma adjustments are preliminary and subject to material change as accounting is finalized.
• The filing is an amendment, indicating that the initial report was incomplete regarding financial disclosures.

Risks

• The pro forma financial information is based on assumptions and estimates that may not materialize, leading to potential deviations from projected results.
• Integration risks associated with combining two companies, which are not explicitly detailed but are inherent in any merger.
• The contingent value rights (CVRs) issued as part of the merger consideration introduce future payment obligations contingent on specific outcomes, such as the Janssen Litigation.

Future Outlook

The filing itself does not provide a future outlook for the combined company. It focuses on disclosing historical financial information of XOMA Royalty and pro forma combined financial information. The pro forma statements are presented for informational purposes and do not represent the actual future results of operations that the combined company may achieve.

Management Comments

• The pro forma financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only, as required by Form 8-K.
• It does not purport to represent the actual results of operations that the Company and XOMA Royalty would have achieved had the companies been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined company may achieve after the merger.

Industry Context

StockSavvy.ai notes that this filing is a standard post-merger disclosure, providing essential financial transparency following the combination of Ligand Pharmaceuticals and XOMA Royalty. The inclusion of detailed financial statements and pro forma data is crucial for investors to assess the financial health and potential of the merged entity within the pharmaceutical and biotechnology sector.

Comparison to Industry Standards

• The filing adheres to SEC requirements for reporting business combinations, specifically Form 8-K/A, which mandates the inclusion of acquired company financial statements and pro forma combined financial information.
• The use of the acquisition method of accounting, as described in the pro forma notes, is standard practice for business combinations under U.S. GAAP.
• The presentation of pro forma financial statements is a common practice in the industry to provide investors with a hypothetical view of the combined entity's financial performance and position.

Legal Proceedings

• The filing references the 'Janssen Litigation' as a source of potential future payments for Contingent Value Rights (CVRs) issued as part of the merger consideration.

Related Party Transactions

• The filing mentions that BVF, a related party, owned approximately 42.8% of Ligand's outstanding common stock as of June 30, 2026. BVF is considered a related party.

Stakeholder Impact

• Shareholders of XOMA Royalty received $39.00 in cash and one contingent value right (CVR) per share, representing a significant event for these stakeholders.
• Ligand Pharmaceuticals shareholders are now owners of a larger, combined entity, with the pro forma financials providing insight into the potential impact.
• Creditors of both Ligand and XOMA Royalty will be subject to the financial health and capital structure of the combined entity.

Next Steps

• Integration of XOMA Royalty's operations and financial reporting into Ligand Pharmaceuticals.
• Finalization of purchase price allocation and accounting for the merger.
• Ongoing reporting of combined financial results in future SEC filings.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the merger completion is a positive step, the filing primarily provides historical and pro forma financial data. The actual performance and integration success of the combined entity remain to be seen, and further operational and financial results will be needed to form a more definitive investment thesis.

Keywords

Merger, Acquisition, Financial Statements, Pro Forma, XOMA Royalty, Ligand Pharmaceuticals, SEC Filing, Amendment